Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy.
J Formos Med Assoc
; 121(1 Pt 1): 58-65, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-33518448
ABSTRACT
BACKGROUND/PURPOSE:
To investigate the impact of pharmaceutical care programs for the management of contraindicated drug-drug interactions (DDIs) in direct-acting antivirals (DAAs) therapy.METHODS:
A prospective observational study was performed at Dalin Tzu Chi Hospital between January 2018 and December 2019. Pharmacists screened DDIs for all hepatitis C patients before DAA therapy. The study outcome included the frequency of contraindicated DDIs, acceptance rate, and cost avoidance of the pharmaceutical care program.RESULTS:
A total of 1053 patients were enrolled in the study, with a mean age of 67.1 ± 11.9 years. Most patients received therapy with sofosbuvir/ledipasvir (37.1%; n = 391), elbasvir/grazoprevir (23.8%; n = 251), or glecaprevir/pibrentasvir (21.1%; n = 222). A total of 796 (75.6%) patients received at least one co-medication, with the average number of co-medications being 5.2 per patient (SD 4.4/patient). In total, 1356 DDIs were identified, with the average DDIs per patient of 1.3 (SD 1.7). For patients with contraindicated DDIs (2%, n = 102), statins and amiodarone were the most common co-medications. Physicians often accepted pharmacists' recommendations (acceptance rate of 72.5%) or withheld co-medication to avoid severe adverse drug events (ADEs). The estimated cost avoidance of preventable ADEs was USD 14,033 for contraindicated DDIs with pharmaceutical care programs.CONCLUSION:
The implementation of pharmaceutical care programs in DAA therapy provides a favorable outcome and substantial cost avoidance.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Assistência Farmacêutica
/
Preparações Farmacêuticas
/
Hepatite C Crônica
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article